African Union, Covax Refuse to Buy More Vaccines From Moderna as Demand Plummets
Get ready for another wave of COVID fearmongering as Big Pharma tries to push a second (then a third, then a fourth…) booster dose as demand wanes (even as scientists warn about a new hybrid mutant strain).
Moderna shares are tumbling on Tuesday after two of the world’s most critical supranational bodies representing low- and middle-income countries have decided not to purchase hundreds of millions of additional doses of the company’s vaccine as a result of waning demand.
The African Union and Covax, the Bill Gates and WHO-backed group dedicated to spreading (low cost) vaccines across the world, made the decision to pass on buying more jabs (while the US rolls out a second booster for older patients) as developing nations struggle to find enough customers eager to be inoculated.
Of course, it’s not just demand that’s keeping vaccination numbers low: According to Bloomberg, developing nations have struggled to turn supplies into inoculations. Lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles and other factors that are hampering distribution.
But outside of China and Hong Kong, COVID cases, deaths and hospitalizations have waned dramatically. This in turn has undermined demand.
What’s more, after more than a year of getting the short end of the stick from Western vaccine makers, developing nations have become resentful, as more consumers take the view that, if they have made it this far without the jabs, then they certainly don’t need them now.
“The vaccine landscape has changed drastically in recent months,” said Safura Abdool Karim, a public-health lawyer and researcher in Johannesburg who’s focused on equity in the pandemic. “We went from really needing vaccines super urgently to now having them.”
While the African Union agreed to purchase 50 million doses during Q1, the organization opted not to acquire another 60 million doses in the second quarter.